Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

Affiliations

• ¹ Yale School of Medicine, New Haven, CT, USA.
• ² Southern California Dermatology, Santa Ana, CA, USA.
• ³ St John's Institute of Dermatology, King's College London, London, UK.
• ⁴ Department of Dermatology, Medical University of Warsaw, Warsaw, Poland.
• ⁵ Rouen University Hospital, INSERM 1234, Normandie University, Rouen, France.
• ⁶ Skin Centre for Dermatology, Canada Probity Medical Research, Waterloo, ON, Canada.
• ⁷ Sinclair Dermatology, Melbourne, VIC, Australia.
• ⁸ Department of Dermatology and Dermatopathology, School of Medicine, University of California, Irvine, CA, USA.
• ⁹ Department of Dermatology, Toulouse University and INSERM infinity U1291, Toulouse, France.
• ¹⁰ Pfizer Inc, New York, NY, USA.
• ¹¹ Pfizer Inc, Groton, CT, USA.
• ¹² Pfizer Inc, 23 Av. du Dr Lannelongue, 75014, Paris, France. alexandre.lejeune@pfizer.com.